Skip to main content
. 2022 Sep 15;84:104268. doi: 10.1016/j.ebiom.2022.104268

Figure 6.

Figure 6

Validating the efficacy of the Writer-Score in the NCC cohort with neoadjuvant immunotherapy. (a) The distribution of Writer-Score in all patients and the heatmap of key genes in the NCC cohort. (b) The Kaplan-Meier curves indicating the difference of DFS between high- and low-score groups. DFS, disease-free survival. (c) The comparison of the Writer-Score between pCR/MPR group and the non-pCR/MPR group. pCR, pathological complete response; MPR, major pathological response. (d) The comparison of the Writer-Score between responder group and the non-responder group. (e) The correlation of the Writer-Score with different immune checkpoint inhibitors. (f) Mutational landscape of the top mutational genes between high and low Writer-Score groups in the NCC cohort. (g) The correlation of Writer-Score with TMB in the NCC cohort. TMB, tumor mutation burden.